LY3143921

CAS No. 1627696-53-0

LY3143921( LY-3143921 | LY 3143921 )

Catalog No. M12416 CAS No. 1627696-53-0

LY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 93 In Stock
10MG 136 In Stock
25MG 229 In Stock
50MG 339 In Stock
100MG 520 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LY3143921
  • Note
    Research use only, not for human use.
  • Brief Description
    LY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively.
  • Description
    LY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively.Solid Tumors Phase 1 Clinical.
  • In Vitro
    LY3177833 (10 μM; 4 days) increases SA-β-gal content in Hep3B cells.Western Blot Analysis Cell Line:Hep3B cells Concentration:10 μM Incubation Time:4 days Result:Increased the expression of human SA-β-gal.
  • In Vivo
    LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dose-dependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation. Animal Model:Female athymic Balb/c nude mice (5-6 weeks old) with SW620 cellsDosage:10.4 mg/kg, 20.8 mg/kg and 31.2 mg/kg Administration:Oral gavage; twice a day for 2 weeksResult:Showed dose dependent antitumor activity in SW620 mouse xenograft tumor model.
  • Synonyms
    LY-3143921 | LY 3143921
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    Cancer
  • Indication
    Solid Tumors

Chemical Information

  • CAS Number
    1627696-53-0
  • Formula Weight
    327.319
  • Molecular Formula
    C16H14FN5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1(C2=C(C=C(C=C2)C3=CNN=C3)C(=O)N1)C4=NC=NC=C4F.O
  • Chemical Name
    (3R)-3-(5-Fluoro-4-pyrimidinyl)-2,3-dihydro-3-methyl-6-(1H-pyrazol-4-yl)-1H-isoindol-1-one hydrate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CDK4/6/1 Inhibitor

    CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).

  • A-674563 HCl (552325...

    A-674563 is an orally available, ATP-competitive, and reversible inhibitor of Akt (Ki: 11 nM for Akt1) .

  • (R)-Enitociclib

    (R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.